ODYY Odyssey Health, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1626644 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-228.8%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-5,799.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets8,303.6%
Debt / equity—
Current ratio0.01x
Interest coverage-0.58x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-4,740.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 | FY20242024-07-31 | FY20232023-07-31 | FY20222022-07-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $0 | $22,625 | $55,166 | $170,000 | — |
| SG&A expense | $912,994 | $1.02M | $2.08M | $2.12M | $2.92M |
| Operating income | -$912,994 | -$1.02M | -$2.14M | -$5.31M | -$8.11M |
| Interest expense | $1.58M | $252,516 | $518,476 | $614,083 | $836,294 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.73M | -$1.74M | -$842,316 | -$5.92M | -$8.44M |
| EBITDA | — | — | -$2.14M | -$5.31M | -$8.10M |
| EPS (basic) | -0.05 | -0.02 | -0.01 | -0.07 | -0.09 |
| EPS (diluted) | -0.05 | -0.02 | -0.01 | -0.07 | -0.09 |
| Weighted avg. shares (diluted) | 108.32M | 104.71M | 97.06M | 82.68M | 89.00M |
| Balance sheet | |||||
| Cash & equivalents | $122,361 | $19,084 | $2,379 | $36,865 | $72,534 |
| Current assets | $147,859 | $49,723 | $56,943 | $405,888 | $526,417 |
| PP&E, net | — | — | — | — | $0 |
| Intangibles | — | — | $0 | $49,905 | $43,260 |
| Total assets | $147,859 | $49,723 | $586,146 | $455,793 | $569,677 |
| Current liabilities | $12.28M | $7.00M | $5.92M | $6.61M | $5.21M |
| Short-term debt | — | — | — | — | $1.18M |
| Total liabilities | $12.28M | $7.00M | $5.92M | $6.61M | $5.21M |
| Shareholders' equity | -$12.13M | -$6.95M | -$5.33M | -$6.16M | -$4.64M |
| Shares outstanding | 105.97M | 96.71M | 96.71M | 79.07M | 77.86M |
| Cash flow statement | |||||
| Operating cash flow | -$1.05M | -$347,392 | -$1.22M | -$1.47M | -$1.47M |
| Investing cash flow | $0 | $69,787 | $1.00M | -$10,061 | — |
| Financing cash flow | $1.15M | $294,310 | $180,724 | $1.45M | $1.45M |
| Depreciation & amortization | — | — | $1,538 | $3,416 | $3,416 |
| Stock-based compensation | $5,408 | $108,399 | $577,805 | $2.82M | — |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.